Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Learn more about:
Related Clinical Trial
Study to Evaluate the Immunogenicity and Safety of LBVD (Hexavalent Vaccine; DTwP-HepB-IPV-Hib Vaccine), Given to Healthy Infants at Primary Series
Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines
Establishing a Controlled Human Infection Model of Bordetella Pertussis
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Pertussis Acellular Vaccine Adjuvanted With TQL1055
Seroprevalence of Pertussis Among Healthy Children and Adolescents in Kazakhstan
A Multi-center Study to Determine the Prevalence and Influence of Pertussis on Subacute Cough in Shenzhen
A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in Shenzhen
Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake
To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Maternal Pertussis Wholecell Responses
Adacel® Booster Vaccination for CMI Assay Development
Pathogenic Bordetella Rapid Detection
5-year Follow-up After a Single Dose Acellular Pertussis Vaccination
Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
Testing the Use of Prompts to Increase Adolescent Immunization Rates
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
CD8 Reactivity to Microorganisms in Blood and Breast Milk
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age
Pilot Study Freeze and Transport Immune Cells
Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
Immunogenicity and Safety of Sanofi Pasteur’s Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
Pentavalent DTaP-Hep B-IPV
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
Evaluation of an Infant Immunization Encouragement Program in Nigeria
A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
How Does the Clinical Tool ‘What’s Going Around’ Affect Clinical Practice
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
Immunology of Non-specific Effects of Vaccine
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths
Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand
Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
Immunogenicity and Safety of Pentaxim in South African Infants
Immunogenicity and Safety of Pentaxim™ in an Indian Population
Boostrix® Pregnancy Registry
Montelukast for Persistent Cough in Young People and Adults
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
Database Surveillance Safety Study of PENTACEL® Vaccine
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
A Study to Assess the Immunogenicity and Safety of GSK Biologicals’ Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks
A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
Protecting Pregnant Women From Infectious Diseases
A Study to Assess the Safety of Adacel® Vaccine
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
Immunogenicity and Safety of Adacel Polio Vaccine
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Confirmatory Study of BK1310 in Healthy Infants
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China
Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)
Influence of BCG on TDaP-IPV Vaccination
A Phase IV Study to Assess the Safety of EupentaTM Inj
Phase I Clinical Trial in Healthy Children
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks
Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Maternal Antibody in Milk After Vaccination
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Safety and Immune Response of Different Pediatric Combination Vaccines.
Sanofi Pasteur’s Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Tdap Vaccination for Infant Caregivers
Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
Post Marketing Surveillance for ADACEL™ in South Korea
Vouchers to Promote Tdap Vaccination
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS
Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults
An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
TDAP Safety in Pregnant Women
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
The Safety of Boostrix Following Routine Immunization of Pregnant Women
Regulatory Post-Marketing Surveillance Study for TETRAXIM™
Tdap Vaccine in Post-Partum Women
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection
Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
Assessing Contacts’ Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
Maternal Tdap Immunization in Guatemala
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 – 12 Years Old
The PertADO Geneva Trial
Study of Adacel® Vaccine Administered to Persons 10 Years of Age
Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibodies Response After a Single Dose of Tdap Vaccine in Thai Pregnant Women
Viaskin Pertussis Vaccine Trial
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose
Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine
The Feasibility of Pertussis Immunization in a Canadian Emergency Department
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
2-year Follow-up After a Single Dose Acellular Pertussis Vaccination
Pertussis Vaccine in Healthy Pregnant Women
Pertussis Vaccination in Pregnant Women
A Study Exploring Whooping Cough Protection in Children and Adults
Immunising Mums Against Pertussis 3
3-year Follow-up After a Single Dose Acellular Pertussis Vaccination
A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
Pertussis Immunization During Pregnancy & HIV Infection
Observational Study Describing the Immune Profile Induced By Pertussis Vaccines
Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare Professionals
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Gambia Pertussis Study (GaPs)
A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults
Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants
Pertussis Infection in Adolescents and Adults With Prolonged Cough
Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients
Optimising the Timing of Whooping Cough Immunisation in MUMs
Bordetella Pertussis Colonisation Challenge Study
Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants
Pertussis (Tdap) Vaccination in Pregnancy